PND46 Patient-Centered Outcomes in Upper Limb Spasticity: Results from a Large International Cohort Study (ULIS-2)  by Balcaitiene, J. et al.
A626  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
A prospective multinational, multicenter (84 centers in 22 countries), observational, 
post-marketing, longitudinal study (ULIS-2), investigating routine use of BoNT-A for 
treating post-stroke ULS. Primary outcome: achievement of the patient’s primary 
goal for treatment using Goal Attainment Scaling (GAS). Goals were set together by 
physicians and patients/caregivers. Patients were able to rate goals for importance. 
Secondary outcome: global assessment of benefits by both physician and patients/
caregiver. Results: Among the 456 adults with post-stroke ULS presenting for 
treatment with BoNT-A, the most commonly selected primary treatment goals were 
passive function (132 (28.9%)), active function (104 (22.8%)), pain (61 (13.4%), and 
impairment (105 (23%)). Patients rated 404/456 primary goals (88.6 %) as “impor-
tant” (395/456 (86.6%) as “very” or “moderately” important), indicating high patient 
involvement in goal-setting. Overall, 363 (79.6%) (95% CI 75.6% to 83.2%) patients 
achieved (or overachieved) their primary goal. GAS T-scores were strongly correlated 
with rating of global benefit and other standard measures (correlations of 0.38 
and 0.63, respectively; p< 0.001). ConClusions: Patient-centered goal setting and 
evaluation using GAS to calculate changes of health-related status is a feasible way 
to capture changes in ULS patient experience. GAS as primary outcome measure in 
ULIS-2 is a step closer to a PRO in ULS patients.
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objeCtives: Clinical trials in epilepsy may not routinely prioritise patient-oriented 
outcomes that consider the harms of treatments in addition to their benefits. To 
date, no systematic empirical research has been undertaken to assess the views of 
people with epilepsy about treatment outcomes. The aim was to identify which out-
comes of drug treatment are considered important to three groups of adults with 
epilepsy: (i) recently diagnosed, (ii) established diagnosis, (iii) women of childbearing 
age. Methods: Semi-structured individual interviews containing ranking exercise 
were used to explore views and interpretations of benefits, harms, and potential life-
impacts of anti-epileptic drug treatments (n= 41); the feasibility of these findings were 
evaluated in focus groups of health care professionals responsible for prescribing anti-
epileptic drugs (n= 8) . Outcomes ranked 1-4 were scored 4-1. For each group, scores 
were summed and divided by the number of participants. Results: Ten recently diag-
nosed men (mean age 45.9), 13 established (mean age 39.3, 92% male), and 18 women of 
childbearing age (mean age 34.5) participated. Reduction in seizure frequency was the 
most highly ranked outcome of drug treatment across all three subgroups (women of 
childbearing age [score]= 2.5, recent= 2.4, established= 2.23). Adults recently diagnosed 
were most concerned about feelings of aggression (1.6), depression (1.0) and ability to 
work (0.9). Adults with established epilepsy were most concerned with ability to work 
(1.15) negative impacts on relationships (1.0), memory problems (0.69), and social-
life (0.69). Women of childbearing age were concerned about memory (1.22), reduced 
independence (0.78), feeling in control (0.56) and foetal abnormality (0.5). Clinicians 
considered life-impacts (eg work, relationships, independence) as consequences of 
benefits and harms of treatment. ConClusions: The importance of remission from 
seizure was consistent. However, patients’ rankings of unfavourable outcomes of drug-
treatment varied by subgroup. Selection of outcome measures in clinical trials in epi-
lepsy must consider relevant patient-oriented outcomes which differ by population.
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objeCtives: Despite being recognised as an important symptom in Fibromyalgia 
(FM), existing measures of fatigue are unlikely to meet regulatory standards for clini-
cal trial endpoints. We therefore describe the development and validation of a new, 
electronically administered patient reported outcome (ePRO) measure of fatigue in FM 
- the Daily Diary of Fatigue Symptoms-Fibromyalgia (DFS-Fibro). This was developed in 
accordance with the FDA regulatory guidance and ISPOR good practice recommenda-
tions for the development and validation of PROs. Methods: Initial item generation 
was based on concept elicitation interviews with 40 FM patients (from the US, Germany 
and France), and clinical relevance of the findings was confirmed by expert clinician 
review. The draft tool was pilot tested with 20 FM patients for 5-9 days, followed by 
cognitive debriefing interviews. A methodology study with 145 FM patients then fol-
lowed, providing data to conduct the psychometric validation of the measure. Both the 
qualitative and quantitative findings were used to finalise the DFS-Fibro. Results: 
Twenty-three items were generated from concept elicitation interviews, including 
items focussed on the physical and cognitive impacts of fatigue as well as fatigue 
‘symptom’ items. Some minor wording revisions were made following pilot testing 
and cognitive debriefing, but none were deleted. All patients found the measure easy 
to understand and use. Initial psychometric analyses supported removing items previ-
ously identified as candidates for deletion in the qualitative work, resulting in a 5-item 
measure focussed on the core symptom of FM fatigue. The psychometric analyses 
were then repeated on the final 5-item measure, which had very high internal consist-
ency (alpha = 0.99), strong test-retest reliability (r > 0.84), and met a priori criteria for 
convergent and known groups validity. ConClusions: The DFS-Fibro development 
followed accepted guidelines and demonstrates strong psychometric properties and 
content validity as a measure of the symptom of fatigue in FM.
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(p< 0,05; p< 0,01). ConClusions: The Spanish version of the MSTCQ questionnaire 
is a feasible, reliable and valid tool for the evaluation of satisfaction with the injec-
tion device in the treatment of MS.
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objeCtives: Diagnosing epilepsy is a lengthy and burdensome process for patients 
and their family. Although the need for a more patient-centered approach in clini-
cal practice is widely acknowledged, empirical evidence regarding patient prefer-
ences for diagnostic modalities in epilepsy is missing. The objectives of this study 
are 1) to identify to what extent important attributes of diagnostic procedures in 
epilepsy affect preferences for a procedure; 2) to determine the relative importance 
of these attributes; and 3) to calculate overall utility scores for routine electroen-
cephalography (EEG) and magnetoencephalography (MEG) registrations. Methods: 
A discrete choice experiment was performed to determine patients’ preferences, 
which involved presentation of pair-wise choice tasks regarding hypothetical sce-
narios. Scenarios varied along six attributes: “Way of measuring brain activity”; 
“Duration”; “Freedom of movement”; “Travel time”; “Type of additional examina-
tion”; and “Chance of additional examination”. Choice tasks were constructed using 
a statistically efficient design and the questionnaire contained 15 unique unlabeled 
choice tasks. Mixed multinomial logistic regression was used to estimate patients’ 
preferences. Results: A total of 289 questionnaires were included in the analysis. 
McFadden’s pseudo R2 showed a model fit of 0.28 and all attributes were statistically 
significant. Heterogeneity in preferences was present for all attributes. “Freedom 
of movement” and “Chance of additional examination” were perceived as the most 
important attributes. Overall utility scores marginally differ between MEG and 
routine EEG. ConClusions: Our study suggests that the identified attributes are 
important in determining patients’ preference for epilepsy diagnostics. It can be 
concluded that MEG is not necessarily more patient-friendly than a routine EEG in 
primary diagnostics and, regarding additional diagnostics, patients have a strong 
preference for long-term 24h EEG over EEG after sleep deprivation. Furthermore, 
barring substantial heterogeneity within the parameters in mind, our study sug-
gests that it is important to take individual preferences into account in clinical 
decision-making.
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objeCtives: Multiple sclerosis (MS) is a chronic neurodegenerative disease affecting 
the central nervous system. There are a variety of symptoms and activity limitations 
associated with MS including mobility problems, muscle spasticity, fatigue and 
mental health problems. In order to gain an accurate insight into the impact of MS 
on patients it is important for accurate patient-reported outcome (PRO) instruments 
to be applied. The purpose of this review was to evaluate the available MS-specific 
PRO measures. Methods: The online literature databases PubMed, Psychinfo and 
Web of Science were used for the search. The search identified all studies that used 
a PRO measure in the study design and was restricted to publications from the 
last fifteen years. Only measures used in at least three clinical trial studies were 
included. The measures identified were evaluated in terms of; source of items, 
item reduction methods, unidimensionality, practicality, responsiveness, reliability, 
internal consistency and face, content and construct validity. Results: The search 
yielded 2317 articles, of which 1066 were duplicates and removed. The review of the 
remaining articles identified six measures that met the review criteria: MSIS-29, 
LMSQoL, MSQoL-54, HAQUAMS, MSQLI and PRIMUS. In addition, the MUSIQoL was 
reviewed because of recent development activity. Most of the measures exhibited 
some weaknesses. Only the PRIMUS performed well on all the review criteria. It 
was the only measure to apply a clear theoretical framework and meet the strict 
measurement requirements of the Rasch model. ConClusions: The PRIMUS is 
recommended for use in clinical trials. The review suggests that many clinical trials 
are using PROs that have not benefitted from the use of Item Response Theory and 
modern psychometric approaches.
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Muscle spasticity following stroke may interfere with motor and activity perfor-
mance, cause pain, and lead to secondary complications. Goals of spasticity man-
agement include improving function (active and passive) and body image, and 
facilitating concomitant treatments. The efficacy of BoNT-A in upper limb spasticity 
(ULS) patients focusing on reduction of muscle tone and pain is well established. 
However, there are no specific ULS patient-reported outcome measures (PROs) avail-
able. As patients with ULS are highly heterogeneous, there is a need to develop meas-
ures to capture realistic, patient-specific treatment goals. objeCtives: To assess 
effectiveness of BoNTA on ULS considering patient-specific experience. Methods: 
